Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Бевацизумаб в лечении HER2-негативного метастатического рака молочной железы: современные данные об эффективности и безопасности
Бевацизумаб в лечении HER2-негативного метастатического рака молочной железы: современные данные об эффективности и безопасности
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Genentech, Inc. US Prescribing Information for Avastin. 2009; http://www.accessdata.fda.gov/ drugsatfda_docs/label/2009/ 125085s0168lbl.pdf.
2. F. Hoffmann-La Roche Ltd. Avastin Summary of Product Characteristics. 2009; http://www. emea.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combinedh582en.pdf.
3. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76.
4. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966–72.
5. Klencke B, Bhattacharya S, Samant M et al. Independent review of E2100 validates progression-free survival (PFS) improvement with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008; 26: 50s (Abstr 1036).
6. Wagner L, Wang M, Miller K et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S239 (abstr.).
7. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of HER2-negative metastatic breast cancer. J Clin Oncol 2010 (in press).
8. Miles DW, Chan A, Romieu G et al. Randomized, double-blind, placebocontrolled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26: 1008s (Abstr LBA1011).
9. Fumoleau P, Greil R, Rayson D et al. Bevacizumab maintenance therapy significantly delays disease progression or death compared with placebo in the AVADO trial. SABCS 2008. post.903.
10. Robert N, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting 2009; 27 (15 Suppl.): Abstr. 1005.
11. O’Shaughnessy J, Miles D, Gray RJ. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol R 2010 (suppl; abstr 1005).
2. F. Hoffmann-La Roche Ltd. Avastin Summary of Product Characteristics. 2009; http://www. emea.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combinedh582en.pdf.
3. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76.
4. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966–72.
5. Klencke B, Bhattacharya S, Samant M et al. Independent review of E2100 validates progression-free survival (PFS) improvement with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008; 26: 50s (Abstr 1036).
6. Wagner L, Wang M, Miller K et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S239 (abstr.).
7. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of HER2-negative metastatic breast cancer. J Clin Oncol 2010 (in press).
8. Miles DW, Chan A, Romieu G et al. Randomized, double-blind, placebocontrolled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26: 1008s (Abstr LBA1011).
9. Fumoleau P, Greil R, Rayson D et al. Bevacizumab maintenance therapy significantly delays disease progression or death compared with placebo in the AVADO trial. SABCS 2008. post.903.
10. Robert N, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting 2009; 27 (15 Suppl.): Abstr. 1005.
11. O’Shaughnessy J, Miles D, Gray RJ. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol R 2010 (suppl; abstr 1005).
Авторы
Л.Г.Жукова
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.